Why the study?
Do anti-Ro/SSA-antibodies impact cardiac arrhythmia risk in the general population?
Do anti-Ro/SSA-antibodies impact cardiac arrhythmia risk in the general population?
This paper discusses the impact of anti-Ro/SSA-antibodies on cardiac arrhythmia risk and underlying electrophysiological mechanisms in the general population.
Anti-Ro/SSA antibodies may confer arrhythmia risk; leaves open prospective validation before screening or risk stratification in general populations.
Impact of anti-Ro/SSA-antibodies on cardiac arrhythmia risk in the general population and putative underlying mechanisms. QTc, corrected QT interval; ICaL, L-type calcium current; AP, action potential; hERG-K+, human ether-a-go-go-related gene potassium channel; IKr, rapid component of the delayed rectifier potassium current; APD, action potential duration.
No takes yet. Share an insight, caveat, or question.
Lazzerini et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: